Current Art Market 2009
HIV market has strong competition among several Marketed and Combination Products
HIV / AIDS – Project analysis of drugs and forecasts 2016 Market
This report provides key data and analysis data on HIV / AIDS in the market. The report provides a comprehensive overview of the annual market data from 2001-2009, and forecasts seven years to 2016. The investigation also includes the characterization of market opportunities, unmet needs associated HIV / AIDS, assessment of competition, product profiles of key marketed products and promising drugs in the pipeline, a summary discontinued projects, the implications for future market competition, and key actors in HIV / AIDS in the market. ( http://www.bharatbook.com/detail.asp?id=134479&rt=HIV-AIDS-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html )
The HIV / AIDS Therapeutics Market is Forecast to show moderate growth for 2016
This analysis suggests that the immunodeficiency virus global human (HIV) / Acquired Immunodeficiency Syndrome (AIDS) market was U.S. $ 12 billion in 2009. Is expected to grow at a compound annual growth rate (CAGR) of 2% for the next seven years to reach 13.7 billion U.S. dollars in 2016. The global market for HIV infection continue to grow between 2009 and 2016 at a moderate pace, due to a variety of maturities of patents in this period. The growth rate is likely to decline from 2012 due to the impact of patents maturities essential medicines. However, migration to the new brand name drugs are likely to minimize the impact of generics. This growth will be driven by moderate increasing prescription rate and increasing use of new drugs such as Atripla, as part of highly active antiretroviral therapy (HAART). The number of people taking treatment HIV is increasing and the average annual cost of antiretroviral therapy (ART) is expected to grow at a faster rate over the next two years, down expected prices from 2012 due to a variety of maturities of patents. The market is characterized by a large unmet need for drugs in terms of efficiency and Drugs that can cure the disease. HAART requires patients to take different kinds of drugs and has achieved near-zero levels of HIV in infected persons however. The increased uptake of HAART and sensitization drive the market. So despite challenges such as lack of a cure and the risk of developing resistance to drugs at the current marketed drugs, the HIV market will grow at a moderate pace.
The market for HIV has strong competition between several Marketed and Combination Products
We analyzed the current competitive landscape for HIV / AIDS, and found the contest to be strong. There are over 30 marketed products from different kinds of therapies for the treatment of HIV. However, all these kinds of drugs are relatively high in safety, but moderate efficacy. This is because there is no cure for the infection in the market. In addition, some new combination of drugs of various kinds have improved the efficiency in terms of reducing HIV levels in the body. Therefore the competing drug on the effectiveness in terms of delaying disease progression and combination medicines are considered much better in this regard. Drugs in the target market today to extend the time it takes for HIV infection to become AIDS. This has led to an increase in average of lives of people infected with HIV. In general, HIV / AIDS in the market is in need of products with profiles of greater efficiency and promise to cure the disease.
The unmet need for cost-effective cure is unlikely to be fulfilled in the coming years
It was found that the global HIV / AIDS is a market highly lucrative market with high levels of unmet need in terms of effectiveness of drugs and cure the disease. The HIV market consists of a large number of drugs that are approved for HIV, but none that can cure the disease. All these medications should be long-term use and duration of therapy may last about 20 years. The anti-HIV drugs on the market are considered safe as the side effects associated with anti-HIV drugs are minimal compared with the effects of progression without treatment of the disease itself. The disease can be fatal and is associated with many opportunistic infections that diminish the quality of life of the infected person. Therefore, while the unmet need for HIV market will remain, some newer drugs may provide better drug treatment for HIV resistance or improved efficiency in terms of frequencies lower dose to improve patient compliance and improve the quality of treatment in the coming years.
Strong clinical pipeline with several molecules first of its kind
We analyzed the HIV / AIDS and the pipe is found to be strong. The pipeline for HIV consists of more than 250 molecules currently in development for various diseases segments. There are many companies active in the development of drugs against HIV. In addition to leading players in the market, Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco are active in the development of drugs for HIV treatment market. The pipeline for HIV / AIDS is as strong as today many pharmaceutical companies are concentrated mainly on new antiviral agents that offer treatment options effective for patients who no longer respond to existing therapies. Consequently, the paradigm of HIV treatment has evolved from monotherapy to triple therapy combination known as HAART. The HIV / AIDS is strong clinical pipeline with several first-in-class molecules in development. Nucleoside reverse transcriptase (NRTI), Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors are the kinds of the most popular drug in which most pipeline activity is taking place today. In total there are 101 molecules first of its kind representing 41% of the pipe. Combination therapy products of various class and I, represent approximately 42% of the clinical pipeline and are expected to improve the safety profiles of marketed drugs.
To learn more and buy a copy of your report please visit: http://www.bharatbook.com/detail.asp?id=134479&rt=HIV-AIDS-Drug-Pipeline-Analysis-and-Market-Forecasts- a-2016.html
O
Contact us at:
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Mail mail: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on Twitter: http://twitter.com/3bbharatbook
About the Author
We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for Market Research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more ur areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com
2009 Art-Tech 2.4Ghz MD500 Hughes electric Helicopter